GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calithera Biosciences Inc (OTCPK:CALA) » Definitions » Asset Turnover

Calithera Biosciences (Calithera Biosciences) Asset Turnover : 0.00 (As of Dec. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Calithera Biosciences Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Calithera Biosciences's Revenue for the three months ended in Dec. 2022 was $0.00 Mil. Calithera Biosciences's Total Assets for the quarter that ended in Dec. 2022 was $32.88 Mil. Therefore, Calithera Biosciences's Asset Turnover for the quarter that ended in Dec. 2022 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Calithera Biosciences's annualized ROE % for the quarter that ended in Dec. 2022 was -118.61%. It is also linked to ROA % through Du Pont Formula. Calithera Biosciences's annualized ROA % for the quarter that ended in Dec. 2022 was -84.38%.


Calithera Biosciences Asset Turnover Historical Data

The historical data trend for Calithera Biosciences's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calithera Biosciences Asset Turnover Chart

Calithera Biosciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 - - 0.10 -

Calithera Biosciences Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Calithera Biosciences's Asset Turnover

For the Biotechnology subindustry, Calithera Biosciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Calithera Biosciences's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calithera Biosciences's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Calithera Biosciences's Asset Turnover falls into.



Calithera Biosciences Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Calithera Biosciences's Asset Turnover for the fiscal year that ended in Dec. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=0/( (64.756+28.676)/ 2 )
=0/46.716
=0.00

Calithera Biosciences's Asset Turnover for the quarter that ended in Dec. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2022 )/( (Total Assets (Q: Sep. 2022 )+Total Assets (Q: Dec. 2022 ))/ count )
=0/( (37.083+28.676)/ 2 )
=0/32.8795
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Calithera Biosciences  (OTCPK:CALA) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Calithera Biosciences's annulized ROE % for the quarter that ended in Dec. 2022 is

ROE %**(Q: Dec. 2022 )
=Net Income/Total Stockholders Equity
=-27.744/23.39
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-27.744 / 0)*(0 / 32.8795)*(32.8795/ 23.39)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.4057
=ROA %*Equity Multiplier
=-84.38 %*1.4057
=-118.61 %

Note: The Net Income data used here is four times the quarterly (Dec. 2022) net income data. The Revenue data used here is four times the quarterly (Dec. 2022) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Calithera Biosciences's annulized ROA % for the quarter that ended in Dec. 2022 is

ROA %(Q: Dec. 2022 )
=Net Income/Total Assets
=-27.744/32.8795
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-27.744 / 0)*(0 / 32.8795)
=Net Margin %*Asset Turnover
= %*0
=-84.38 %

Note: The Net Income data used here is four times the quarterly (Dec. 2022) net income data. The Revenue data used here is four times the quarterly (Dec. 2022) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Calithera Biosciences Asset Turnover Related Terms

Thank you for viewing the detailed overview of Calithera Biosciences's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Calithera Biosciences (Calithera Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.
Executives
Deepika Pakianathan director, 10 percent owner 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Takeda Ventures, Inc. 10 percent owner 9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Keith Orford officer: SR. VP, CLINICAL DEVELOPMENT CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Jonathan G Drachman director 21823 30TH DRIVE SE, BOTHELL WA 98021
Susan Molineaux director, officer: PRESIDENT AND CEO C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
Christopher Molineaux officer: SR. VP, DEVELOPMENT CALITHERA BIOSCIENCES, 343 OYSTER POINT, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Emil Kuriakose officer: CHIEF MEDICAL OFFICER 343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Millennium Pharmaceuticals Inc 10 percent owner 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Stephanie Wong officer: VP, FINANCE 343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO CA 94080
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104